The FDA has approved golimumab for the treatment of children with moderately to severely active ulcerative colitis who weigh at least 15 kg.The approval expands upon the existing golimumab (Simponi, ...
The Food and Drug Administration (FDA) has expanded the approval of Simponi ® (golimumab) to include pediatric patients weighing at least 15kg with moderate to severely active ulcerative colitis (UC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback